La vendita allo scoperto per Haemonetics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Haemonetics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Haemonetics (NYSE:HAE) Azioni, Report sulle vendite allo scoperto

Haemonetics

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Haemonetics Corp

HAEMATO AG

<p>Barrington Research  analyst Michael Petusky   maintains Haemonetics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAE#NYSE">HAE</a>) with a Outperform and maintains $108 price target.</p>


News

Price Target

Analyst Ratings

Barrington Research Maintains Outperform on Haemonetics, Maintains $108 Price Target

<p>In the latest quarter, 7 analysts provided ratings for Haemonetics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAE#NYSE">HAE</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Haemonetics, presenting an average target of $107.29, a high estimate of $125.00, and a low estimate of $85.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 3.99%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731067249_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>A clear picture of Haemonetics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Cooper</td>
<td>Raymond James</td>
<td>Maintains</td>
<td>Strong Buy</td>
<td>$120.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$108.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Kristen Stewart</td>
<td>CL King</td>
<td>Announces</td>
<td>Buy</td>
<td>$116.00</td>
<td>-</td>
</tr>
<tr>
<td>Craig Bijou</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Neutral</td>
<td>$85.00</td>
<td>-</td>
</tr>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$112.00</td>
<td>-</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$125.00</td>
<td>$125.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Haemonetics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Haemonetics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Haemonetics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Haemonetics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/HAE/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Haemonetics analyst ratings.</strong></a></p>
<h2>All You Need to Know About Haemonetics</h2>
<p>Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.</p>
<h3>Key Indicators: Haemonetics's Financial Health</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Revenue Growth:</strong> Haemonetics displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>7.98%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Haemonetics's net margin is impressive, surpassing industry averages. With a net margin of <strong>11.41%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>4.11%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Haemonetics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.62%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Haemonetics's debt-to-equity ratio is below the industry average. With a ratio of <b>1.35</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Deep Dive Into Haemonetics Stock: Analyst Perspectives (7 Ratings)

<p>Raymond James  analyst Andrew Cooper   upgrades Haemonetics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAE#NYSE">HAE</a>) from Outperform to Strong Buy and maintains the price target from $120 to $120.</p>


Upgrades

Raymond James Upgrades Haemonetics to Strong Buy, Maintains Price Target to $120

WIIM

Haemonetics shares are trading higher after the company reported better-than-expected Q2 financial results.

Guidance

Haemonetics Reiterated FY25 Adjusted Earnings Per Diluted Share Outlook Of $4.45-$4.75 Vs. $4.59 Estimate

Haemonetics Projects Total Company FY25 Reported Revenue Growth Of 5%-8% (Reiterated); Sees Organic Revenue Growth Of 1%-4% (Prior View: 0-3%)

<p>Haemonetics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAE#NYSE">HAE</a>) reported quarterly earnings of $1.12 per share which beat the analyst consensus estimate of $1.07 by 4.67 percent. The company reported quarterly sales of $345.511million &nbsp;which beat the analyst consensus estimate of $342.648 million by 100.00 percent. This is a 100.00 percent decrease over sales of $318.183 million the same period last year.</p>


Earnings

Earnings Beats

Earnings Misses

Haemonetics Q2 2025 Adj. EPS $1.12 Beats $1.07 Estimate, Sales $345.511M Beat $342.648M Estimate

<p>CL King  analyst Kristen Stewart   initiates coverage on Haemonetics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAE#NYSE">HAE</a>) with a Buy rating and announces Price Target of $116.</p>


Initiation

CL King Initiates Coverage On Haemonetics with Buy Rating, Announces Price Target of $116

<p>B of A Securities  analyst Craig Bijou   initiates coverage on Haemonetics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAE#NYSE">HAE</a>) with a Neutral rating and announces Price Target of $85.</p>


B of A Securities Initiates Coverage On Haemonetics with Neutral Rating, Announces Price Target of $85

<p>Haemonetics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAE#NYSE">HAE</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $107.5, along with a high estimate of $125.00 and a low estimate of $85.00. A decline of 1.08% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1725976892_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>A clear picture of Haemonetics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$112.00</td>
<td>-</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$125.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$108.00</td>
<td>$107.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Haemonetics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Haemonetics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Haemonetics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Haemonetics's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/HAE/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Haemonetics analyst ratings.</strong></a></p>
<h2>Discovering Haemonetics: A Closer Look</h2>
<p>Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.</p>
<h3>A Deep Dive into Haemonetics's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Haemonetics showcased positive performance, achieving a revenue growth rate of <strong>7.98%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>11.41%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Haemonetics's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>4.11%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Haemonetics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.62%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>1.35</strong>, Haemonetics adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


What Analysts Are Saying About Haemonetics Stock

<p>BTIG  analyst Marie Thibault   initiates coverage on Haemonetics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAE#NYSE">HAE</a>) with a Buy rating and announces Price Target of $112.</p>


BTIG Initiates Coverage On Haemonetics with Buy Rating, Announces Price Target of $112

<p>Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Haemonetics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAE#NYSE">HAE</a>) in the last three months.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $107.5, a high estimate of $125.00, and a low estimate of $85.00. Experiencing a 1.08% decline, the current average is now lower than the previous average price target of $108.67. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1724342419_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>A clear picture of Haemonetics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$125.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$108.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Announces</td>
<td>Buy</td>
<td>$112.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Haemonetics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Haemonetics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Haemonetics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Haemonetics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/HAE/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Haemonetics analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Haemonetics</h2>
<p>Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.</p>
<h3>Key Indicators: Haemonetics's Financial Health</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Revenue Growth:</strong> Haemonetics displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>7.98%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Haemonetics's net margin is impressive, surpassing industry averages. With a net margin of <strong>11.41%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Haemonetics's ROE excels beyond industry benchmarks, reaching <strong>4.11%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Haemonetics's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.62%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>1.35</strong>, Haemonetics adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Expectations For Haemonetics's Future

<p>Citigroup  analyst Joanne Wuensch   maintains Haemonetics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAE#NYSE">HAE</a>) with a Neutral and lowers the price target from $94 to $85.</p>


Citigroup Maintains Neutral on Haemonetics, Lowers Price Target to $85

<p>The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.</p>
<p>The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.</p>
<p>Here's the latest list of major oversold players in this sector, having an RSI near or below 30.</p>
<h3 class="wp-block-heading"><strong>Haemonetics Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAE#NYSE">HAE</a>)</strong></h3>
<ul>
<li>On Aug. 8, Haemonetics posted better-than-expected quarterly earnings. The company's stock fell around 19% over the past month and has a <a href="https://www.benzinga.com/quote/HAE">52-week low of $70.74</a>.</li>
<li><strong>RSI Value:</strong> 25.47</li>
<li><strong>HAE Price Action:</strong> Shares of Haemonetics gained 1.1% to close at $73.99 on Thursday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent081624&amp;t=be2bearmibe3na1">latest HAE news.</a></li>
</ul>
<p><figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent081624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="835" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/16045915/image-128.png" alt="" class="wp-image-498427" style="width:606px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/16045915/image-128.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/16045915/image-128-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/16045915/image-128-768x711.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure></p>
<h3 class="wp-block-heading"><strong>Immunitybio Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></h3>
<ul>
<li>On Aug. 6, ImmunityBio announced study of ANKTIVA in combination with the AdHER2DC cancer vaccine as a potential therapy to control endometrial cancer. The company's stock fell around 38% over the past month. It <a href="https://www.benzinga.com/quote/IBRX">has a 52-week low</a> of $1.25.</li>
<li><strong>RSI Value:</strong> 29.87</li>
<li><strong>IBRX Price Action:</strong> Shares of Immunitybio rose 2.6% to close at $3.98 on Thursday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent081624&amp;t=be2bearmibe3na1">trend in IBRX stock</a>.</li>
</ul>
<p><figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent081624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="916" height="828" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/16050020/image-129.png" alt="" class="wp-image-498429" style="width:589px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/16050020/image-129.png 916w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/16050020/image-129-300x271.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/16050020/image-129-768x694.png 768w" sizes="(max-width: 916px) 100vw, 916px" /></a></figure></p>
<h3 class="wp-block-heading"><strong>Progyny Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGNY#NASDAQ">PGNY</a>)</strong></h3>
<ul>
<li>On Aug. 6, Progyny reported worse-than-expected second-quarter revenue results. &#8220;The rate of utilization in the second quarter was consistent with our expectations, indicating that the demand for treatment remains both healthy and within the range of our long-established patterns,&#8221; said Pete Anevski, Chief Executive Officer of Progyny. The company's shares fell around 31% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/PGNY">low of $19.60</a>.</li>
<li><strong>RSI Value:</strong> 29.06</li>
<li><strong>PGNY Price Action:</strong> Shares of Progyny rose 1.7% to close at $20.85 on Thursday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent081624&amp;t=be2bearmibe3na1">breakout in PGNY shares</a>. </li>
</ul>
<p><figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent081624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="882" height="832" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/16050145/image-130.png" alt="" class="wp-image-498432" style="width:483px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/16050145/image-130.png 882w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/16050145/image-130-300x283.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/16050145/image-130-768x724.png 768w" sizes="(max-width: 882px) 100vw, 882px" /></a></figure></p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40394036/jim-cramer-recommends-buying-clorox-ceo-has-done-remarkable-job">Jim Cramer Recommends Buying Clorox: &#8216;CEO Has Done Remarkable Job&#8217;</a></strong></li>
</ul>


Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

IBRX

PGNY

Top 3 Health Care Stocks That Are Set To Fly This Quarter

Health Care

General

Haemonetics Announced The Full Market Release Of Its Vascade MVP XL Mid-bore Venous Closure System As The Newest Addition To Haemonetics' Vascade Portfolio Of Vascular Closure Systems Featuring Collapsible Disc Technology And A Proprietary Resorbable Collagen Patch To Promote Rapid Hemostasis

<p>JMP Securities  analyst David Turkaly   reiterates Haemonetics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAE#NYSE">HAE</a>) with a Market Outperform and maintains $125 price target.</p>


Reiteration

JMP Securities Reiterates Market Outperform on Haemonetics, Maintains $125 Price Target

<p>Barrington Research  analyst Michael Petusky   maintains Haemonetics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAE#NYSE">HAE</a>) with a Outperform and raises the price target from $107 to $108.</p>


Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $108

Haemonetics shares are trading lower. The company reported Q1 financial results.

Haemonetics Reaffirms Fiscal 2025 Guidance: Projects Adjusted Earnings Per Diluted Share Of $4.45-$4.75 Vs. $4.6 Estimate

Haemonetics Corporation (HAE) Q1 2025 Earnings Call Transcript

JMP Securities analyst David Turkaly has reiterated their bullish stance on HAE stock, giving a Buy rating on August 9. David Turkaly has given his...

Haemonetics Corporation: Strong Growth and Innovation Justify a Buy Rating

Haemonetics (HAE) has received a new Buy rating, initiated by BTIG analyst, Marie Thibault. Marie Thibault's rating is based on an assessment of Ha...

Haemonetics: A Solid Investment in MedTech with Promising Growth and Valuation Upside

Barrington analyst Michael Petusky has maintained their bullish stance on HAE stock, giving a Buy rating on September 13. Michael Petusky has given...

Buy Rating Affirmed for Haemonetics with Promising Growth in Hospital Segment and Strong Plasma Market Position

Haemonetics Non-GAAP EPS of $1.12 beats by $0.05, revenue of $346M beats by $3.42M

Haemonetics (HAE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Matson from Needh...

Haemonetics Earns Buy Rating for Strong Q2 Performance and Margin Improvements

Haemonetics ( ($HAE) ) has released its Q2 earnings. Here is a breakdown of the information Haemonetics presented to its investors. Haemonetics Cor...

Haemonetics' Q2 2025 Earnings Show Strong Growth

David Turkaly, an analyst from JMP Securities, reiterated the Buy rating on Haemonetics (HAE – Research Report). The associated price target remain...

Haemonetics' Strong Financial Performance and Growth Potential Drive Buy Rating with $125 Price Target

Michael Petusky, an analyst from Barrington, maintained the Buy rating on Haemonetics (HAE – Research Report). The associated price target remains ...

Comments

Haemonetics

Vendite allo scoperto

Haemonetics (NYSE:HAE) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO